SCHEMBL4953870

SCHEMBL4953870

COC1C[C@H](CO)[C@@H](CO)O1

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 2/20 0.31
▸ MGAM O43451 2/20 0.30
▸ SI P14410 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8184048 1.00 STAT3 (0.31) STAT3MGAMSI
SCHEMBL4953874 0.86 — —
SCHEMBL8045018 0.79 OGA (0.37) STAT3MGAMSI
SCHEMBL662016 0.79 OGA (0.37) STAT3MGAMSI
SCHEMBL6142431 0.79 OGA (0.37) STAT3MGAMSI
SCHEMBL15445060 0.79 STAT3 (0.33) STAT3MGAMSI
SCHEMBL6438566 0.79 MGAM (0.30) MGAMSI
SCHEMBL12154805 0.79 OGA (0.37) STAT3MGAMSI
SCHEMBL9999673 0.79 OGA (0.37) STAT3MGAMSI
SCHEMBL13497166 0.79 OGA (0.37) STAT3MGAMSI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101502531-A 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections PHARMASSET INC (US) 2009-08-12 — — CN disclosed
EP-1284741-B1 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS PHARMASSET INC (US) 2008-11-19 — — EP disclosed
EP-1964569-A2 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections Pharmasset, Inc. (US) 2008-09-03 — — EP disclosed
US-7094770-B2 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections PHARMASSET, LTD. (BB) 2006-08-22 — — US disclosed
EP-1284741-A2 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS Pharmasset, Ltd. (BB) 2003-02-26 — — EP disclosed
US-20020055483-A1 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections PHARMASSET, INC. 2002-05-09 — — US disclosed
WO-2001079246-A2 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS PHARMASSET, LTD. (BB) 2001-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055483-A1 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections HCCS, HDGF, HMBS STAT3 3912/4885MGAM 2643/4885SI 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback